5-Propyl-1-pyridin-2-yl-1H-pyrazole-4-carbonyl chloride | 706819-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-Propyl-1-pyridin-2-yl-1H-pyrazole-4-carbonyl chloride
• CAS: 706819-93-4
• 化学式: C₁₂H₁₂ClN₃O
• 分子量: 249.7
• InChiKey: QYZGHOYQKDHAID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  47.78
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  5-Propyl-1-pyridin-2-yl-1H-pyrazole-4-carbonyl chloride 以 丙酮 为溶剂， 反应 7.0h， 生成 5-Methylsulfanyl-4-[4-(5-propyl-1-pyridin-2-yl-1H-pyrazol-4-yl)-thiazol-2-yl]-thiophene-2-carboxylic acid methyl ester
  参考文献：
  名称：

  A novel series of potent and selective small molecule inhibitors of the complement component C1s

  摘要：

  Activation of the classical pathway of complement has been implicated in disease states such as hereditary angioedema, ischemia-reperfusion injury and acute transplant rejection. The trypsin-like serine protease C1s represents a pivotal upstream point of control in the classical pathway of complement activation and is therefore likely to be a useful target in the therapeutic intervention of these disease states. A series of thiopheneamidine-based inhibitors of C1s has been optimized to give a 70 nM inhibitor that inhibits the classical pathway of complement activation in vitro. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.034
• 作为产物：
  描述：

  丁酰乙酸乙酯 在 sodium hydroxide 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 8.0h， 生成 5-Propyl-1-pyridin-2-yl-1H-pyrazole-4-carbonyl chloride
  参考文献：
  名称：

  A novel series of potent and selective small molecule inhibitors of the complement component C1s

  摘要：

  Activation of the classical pathway of complement has been implicated in disease states such as hereditary angioedema, ischemia-reperfusion injury and acute transplant rejection. The trypsin-like serine protease C1s represents a pivotal upstream point of control in the classical pathway of complement activation and is therefore likely to be a useful target in the therapeutic intervention of these disease states. A series of thiopheneamidine-based inhibitors of C1s has been optimized to give a 70 nM inhibitor that inhibits the classical pathway of complement activation in vitro. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.034